High- and Moderate-Risk Variants Among Breast Cancer Patients and Healthy Donors Enrolled in Multigene Panel Testing in a Population of Central Russia
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252312640 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Syuykum Shumilova und 9 weiteren Autor:innen. Beteiligte Einrichtung: Engelhardt Institute of Molecular Biology, the Russian Academy of Sciences, 119991 Moscow, Russia. Hauptthemen laut MEDLINE: Breast Neoplasms, Genetic Predisposition to Disease, Genetic Testing, DNA Repair. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Russian Ministry of Science and High Education, Russian Ministry of Science and High Education.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Assessments of breast cancer (BC) risk in carriers of pathogenic variants identified by gene panel testing in different populations are highly in demand worldwide. We performed target sequencing of 78 genes involved in DNA repair in 860 females with BC and 520 age- and family history-matched controls from Central Russia. Among BC patients, 562/860 (65.3%) were aged 50 years or less at the time of diagnosis. In total, 190/860 (22%) BC patients were carriers of 198 pathogenic/likely pathogenic (P/LP) variants in 30 genes, while among controls, 32/520 (6.2%) carriers of P/LP variants in 17 genes were identified. The odds ratio [95% confidence interval] was 16.3 [4.0–66.7] for BRCA1; 12.0 [2.9–45.9] for BRCA2; and 7.3 [0.9–56.7] for ATM (p < 0.05). Previously undescribed BRCA1/2, ATM, and PALB2 variants, as well as novel recurrent mutations, were identified. The contribution to BC susceptibility of truncating variants in the genes BARD1, RAD50, RAD51C, NBEAL1 (p. E1155*), and XRCC2 (p. P32fs) was evaluated. The BLM, NBN, and MUTYH genes did not demonstrate associations with BC risk. Finding deleterious mutations in BC patients is important for diagnosis and management; in controls, it opens up the possibility of prevention and early diagnostics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Engelhardt Institute of Molecular Biology, the Russian Academy of Sciences, 119991 Moscow, Russia.
- SBHI Moscow Clinical Scientific Center named after Loginov of Moscow Healthcare Department, 111123 Moscow, Russia.
ORCID-Profile: Syuykum Shumilova, Sergey Nikolaev, George Krasnov, Anna Ikonnikova, Tatiana Nasedkina
Förderung
- the Russian Ministry of Science and High Education
- Russian Ministry of Science and High Education
Zitieren
APA
Shumilova, S., Danishevich, A., Nikolaev, S., Krasnov, G., Ikonnikova, A., Isaeva, D., Surzhikov, S., Zasedatelev, A., Bodunova, N., & Nasedkina, T. (2024). High- and Moderate-Risk Variants Among Breast Cancer Patients and Healthy Donors Enrolled in Multigene Panel Testing in a Population of Central Russia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252312640
Vancouver
Shumilova S, Danishevich A, Nikolaev S, Krasnov G, Ikonnikova A, Isaeva D, et al. High- and Moderate-Risk Variants Among Breast Cancer Patients and Healthy Donors Enrolled in Multigene Panel Testing in a Population of Central Russia. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252312640
BibTeX
@article{Shumilova2024,
author = {Shumilova, Syuykum and Danishevich, Anastasia and Nikolaev, Sergey and Krasnov, George and Ikonnikova, Anna and Isaeva, Darya and Surzhikov, Sergei and Zasedatelev, Alexander and Bodunova, Natalia and Nasedkina, Tatiana},
title = {High- and Moderate-Risk Variants Among Breast Cancer Patients and Healthy Donors Enrolled in Multigene Panel Testing in a Population of Central Russia},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252312640}
}
EUVIMED